Респираторная медицина. Руководство (в 2-х томах)
Шрифт:
47. Engel T, Dirksen A, Heinig JH, Nielsen NH, Weeke B, Johansson SA. Single-dose inhaled budesonide in subjects with chronic asthma. Allergy. 1991 Oct;46(7):547-53.
48. Rodrigo GJ. Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma. Am J Respir Crit Care Med. 2005 Jun 1;171(11):1231-6. Epub 2005 Mar 11.
49. Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma exacerbations and poor asthma control. Lancet 1999;353(9150):364-9.
50. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999;159(4 Pt 1):1043-51.
51. Meltzer EO, Wenzel S. The efficacy and safety of mometasone furoate delivered via a dry powder inhaler for the treatment of asthma. J Asthma. 2006 Dec;43(10):765-72.
52. Selroos O, Edsbacker S, Hultquist C. Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation. J Asthma. 2004;41(8):771-90.
53. Toogood JH, Baskerville JC, Jennings B, Lefcoe NM, Johansson SA. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol 1982;70(4):288-98.
54. Boudinot FD, D'Ambrosio A, Jusko WJ: Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm 1986; 14:469-493.
55. Masoli M., Holt S., Weatherall M., Beasley R. Dose-response relationship of inhaled budesonide
56.in adult asthma: a meta-analysis. Eur Respir J 2004; 23: 552 - 558.
57. Holt S, Suder A, Weatherall M et al. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001;323:1 - 8
58. Chikanza IC, Kozaci D, Chernajovsky Y. The molecular and cellular basis of corticosteroid resistance. J Endocrinol. 2003 Dec;179(3):301-10.
59. Pedersen, S., and O. R. Hansen. 1995. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J. Allergy Clin. Immunol. 95:29 - 33.
60. Alving, K., J. O. N. Lundberg, and S. L. Nordvall. 1995. Dose-dependent reduction of exhaled nitric oxide in asthmatic children by in haled steroids (abstract). Am. J. Respir. Crit. Care Med. 151:A129.
61. Malmstrom, K, Rodriguez-Gomez, G, Guerra, J, et al Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999;130,487-495
62. Phillipps GH, Bailey EJ, Bain BM, et al. Synthesis and structure-activity relationships in a series of anti-inflammatory corticosteroid analogues, halomethyl androstane-17beta-carbothioates and -17beta-carboselenoates. J Med Chem 1994; 37:3717 - 3729
63. Belvisi M, Bundschuh D, Stoeck M, et al. Ciclesonide, a novel on site activatedinhaled corticosteroid with potent anti-inflammatory actions in the airways [abstract]. J Allergy Clin Immunol 2002; 109(suppl):59
64. Chapman KR, Patel P, D’Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005; 60:330 - 337
65. Systematic Review of the Evidence Regarding Potential Complications of Inhaled Corticosteroid Use in Asthma. Chest 2003;124;2329-2340
66. Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK: Frequency of voice problems and cough in patients using pressurised aersosol inhaled steroid preparations. Eur. Respir. J. 1995; 8:590-592.
67. Toogood JA, Jennings B, Greenway RW, Chung L: Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J. Allergy Clin. Immunol. 1980; 65:145-153.
68. Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. New England Journal of Medicine. 2000;343:1054-1063.
69. Agertoft L, et al. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. New England Journal of Medicine. 2000;343:1064-1069.
70. Poolson JB, Kazanowski JJ, Goldman AL, Szentivanyi A: Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline. Clin. Exp. Pharmacol. Physiol. 1978; 5:535-539.
71. Pauwels RA, Joos GF: Characterization of the adenosine receptors in the airways. Arch. Int. Pharmacodyn. Ther. 1995; 329:151-156.
72. Ishizaki T, Minegishi A, Morishita A, et al: Plasma catecholamine concentrations during a 72 hour aminophylline infusion in children with acute asthma. J. Allergy Clin. Immunol. 1988; 92:146-154.
73. Horrobin DF, Manku MS, Franks DJ, Hamet P: Methylxanthine phosphodiesterase inhibitors behave as prostaglandin antagonists in a perfused rat mesenteric artery preparation. Prostaglandins 1977; 13:33-40.
74. Spatafora M, Chiappara G, Merendino AM, D’Amico D, Bellia V, Bonsignore G: Theophylline suppresses the release of tumour necrosis factor-alpha by blood monocytes and alveolar macrophages. Eur. Respir. J. 1994; 7:223-228.
75. Aubier M, De Troyer A, Sampson M, Macklem PT, Roussos Ch: Aminophylline improves diaphragmatic contractility. N. Engl. J. Med. 1981; 305:249-252.
76. Jusko WJ, Gardner MJ, Mangiore A, Schentag JJ, Kopp JR, Vance JW: Factors affecting aminophylline clearance: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates and ethanol. J. Pharm. Sci. 1979; 68:1358-1366.
77.
– 1998 Jun.
– V. 157, 6 Pt 2.
– P. 214-218